 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
12 News |  |
- ||| Strefen / Reckitt Benckiser
Review, Adverse events: A systematic review of flurbiprofen 8.75 (Pubmed Central) - Mar 21, 2024
Results from this systematic review on the risk of non-haemorrhagic events did not provide evidence for these events occurring as a result of interaction with other medicinal products. Additional appropriately designed studies would be required to confirm whether these findings suggest a true absence of risk or limitations in reporting.
- || Strefen / Reckitt Benckiser
PK/PD data, Journal: Relationship between Pharmacokinetic Profile and Clinical Efficacy Data of Three Different Forms of Locally Applied Flurbiprofen in the Mouth/Throat. (Pubmed Central) - Jul 29, 2023
These pAUCs provide useful data that allow for the discrimination between formulations. Moreover, the pAUC values represent <5% of the total AUC, suggesting that the early onset of pain relief is a response to immediate local absorption at the site of action rather than a systemic effect.
- ||| Strefen / Reckitt Benckiser
New P1 trial, Reflex: Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients With Upper Respiratory Tract Infections (clinicaltrials.gov) - Jul 21, 2023
P1, N=120, Recruiting, Sponsor: University of Melbourne
- | Strefen / Reckitt Benckiser
Preclinical, Journal: Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. (Pubmed Central) - Feb 22, 2022
Ibuprofen, flurbiprofen, etoricoxib and paracetamol demonstrated no effects on ACE2 expression or activity in vitro or in vivo. Higher concentrations of ibuprofen and flurbiprofen reduced SARS-CoV-2 replication in vitro.
- || Strefen / Reckitt Benckiser, Ocufen (flurbiprofen ophthalmic solution) / AbbVie
Review, Journal: A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events. (Pubmed Central) - Aug 24, 2021
Counts were low across all studies and results comparing flurbiprofen and placebo treatment arms were non-significant. However, scarcity of studies and low certainty of evidence for the outcome of haemorrhagic events limits the conclusions of this systematic review.
- || Strefen / Reckitt Benckiser
Clinical, Journal: Evidence of the Efficacy of Flurbiprofen 8.75 mg Lozenges for Patients Receiving Antibiotics for Laboratory-Confirmed Streptococcal Pharyngitis. (Pubmed Central) - Jul 16, 2021
Irrespective of antibiotic use, flurbiprofen 8.75 mg lozenges provide well-tolerated, effective relief of pharyngeal symptoms in patients with streptococcal infection. In the 24 hours after administration, antibiotics provide no relief of throat pain or difficulty swallowing beyond the topical demulcent effects of placebo lozenges.
- ||||| Strefen / Reckitt Benckiser
Enrollment change: A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis (clinicaltrials.gov) - Sep 21, 2017
P3, N=204, Completed, Sponsor: Reckitt Benckiser LLC
In the 24 hours after administration, antibiotics provide no relief of throat pain or difficulty swallowing beyond the topical demulcent effects of placebo lozenges. N=300 --> 204
- ||||| Strefen / Reckitt Benckiser
Enrollment change: A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis (clinicaltrials.gov) - Sep 21, 2017
P3, N=198, Completed, Sponsor: Reckitt Benckiser LLC
N=300 --> 204 N=300 --> 198
- |||||||||| Strefen / Reckitt Benckiser
New P3 trial: Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method (clinicaltrials.gov) - Nov 14, 2013
P3, N=120, Recruiting, Sponsor: Reckitt Benckiser LLC